Selumetinib (AZD6244) CAS 606143-52-6 Purity >99.0% (HPLC) MEK1/2 Inhibitor
Ruifu Chemical is the leading manufacturer of Selumetinib (AZD6244) (CAS: 606143-52-6) with high quality, is a potent and highly selective MEK inhibitor, mainly for the treatment of advanced non-small cell lung cancer (NSCLC). Ruifu Chemical has been supplying pharmaceutical intermediates and APIs more than 15 years.
Ruifu Chemical can provide worldwide delivery, competitive price, excellent service.
Purchase Selumetinib (AZD6244) or other products, please contact us by e-mail: alvin@ruifuchem.com
| Chemical Name | Selumetinib |
| Synonyms | AZD6244; AZD-6244; AZD 6244; ARRY 142886; ARRY-142886; 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; 6-(4-Bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide |
| Stock Status | In Stock |
| CAS Number | 606143-52-6 |
| Molecular Formula | C17H15BrClFN4O3 |
| Molecular Weight | 457.68 g/mol |
| Melting Point | >219℃(dec.) |
| Density | 1.692 |
| Refractive Index n20/D | 1.672 |
| Solubility | Soluble in DMSO (92 mg/ml at 25℃), Water (<1 mg/ml at 25℃) |
| Storage Temperature | Store Long-Term at -20℃ |
| Shipping Temperature | Shipped Under Ambient Temperature for Short Term |
| Stability | Stable For 1 Year From Date of Purchase as Supplied |
| COA & MSDS | Available |
| Origin of Product | Shanghai, China |
| Application(s) | A Potent and Selective MEK1/2 Inhibitor |
| Caution | Not For Human or Veterinary Use. For Research Use Only. |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | White to Off-White Powder | White Powder |
| Selumetinib Purity | >99.0% (HPLC) | 99.45% |
| 1H NMR Spectrum | Consistent with Structure | Conforms |
| LC-MS | Consistent with Structure | Conforms |
| Conclusion | The product has been tested and complies with the given specifications | |
Package: Bottle, or according to customer's requirement.
Storage Condition: Keep the container tightly closed. Store long-term at -20℃. Keep away from incompatible substances. Keep away from sunshine; avoid fire and heat sources. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
| HS Code | 2934999099 |
Selumetinib (AZD6244) (CAS: 606143-52-6) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib inhibits ERK1/2 phosphorylation. Selumetinib is a tight-binding, uncompetitive inhibitor of mitogen-activated protein kinase kinases (MEK) 1 and 2 currently in clinical development. It is useful as biomarker in human lung cancer cell. Potent MEK inhibitor.
Selumetinib, mainly for the treatment of advanced non-small cell lung cancer (NSCLC). Currently, Selumetinib is in phase III clinical trials for the treatment of non-small cell lung cancer. Selumetinib was developed by British company AstraZeneca and is used to treat advanced non-small cell lung cancer (NSCLC). Selumetinib is mainly used to treat bile duct cancer, colon cancer, NSCLC, etc. Currently, Selumetinib is in stage III clinical trials for treatment of NSCLC.
Selumetinib is an orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.
